ABSTRACT
Measurement of plasma levels of natriuretic peptides has been used to assess left ventricular dysfunction and prognosis. Recently levels of the N-terminal peptide fragment of the precursor of brain natriuretic peptide have been reported to be present in peripheral plasma and to be increased in chronic heart failure patients. Our aim in this study was to develop a radioimmunoassay for N-terminal proBNP, to compare its plasma concentrations in control subjects and in patients with end-stage heart failure and to define its relation to brain natriuretic peptide (BNP). A polyclonal antibody was raised in rabbits against human N-terminal proBNP fragment (amino acid 1-21). The plasma N-terminal proBNP concentrations were assayed directly without extraction. No detectable cross-reactivity existed with other natriuretic peptides: BNP, ANP or N-terminal proANP. The assay had a detection limit (2 SD from zero) of 9.7 pmol/L. Plasma N-terminal proBNP was 29 (13-75) (median (range)) pmol/L in the control group. There were no gender difference, male: 28 (13-61) vs. female 33 (13-75) pmol/L, p= NS, but there was a positive correlation to age (r=0.52, p<0.0001). In patients with end-stage heart failure the median N-terminal proBNP levels were increased significantly 616 (114-2781) pmol/L (p<0.001) and in pooled data N-terminal proBNP showed a close correlation to BNP (r=0.96, p<0.0001). Size exclusion of plasma extracts indicated that proBNP (1-108) may circulate both as intact prohormone and as split products, N-terminal proBNP (1-76) and BNP (77-108). Our results support the concept that N-terminal proBNP measurement could be a valuable tool in the biochemical indication of increased cardiac wall stress.
Subject(s)
Nerve Tissue Proteins/blood , Peptide Fragments/blood , Radioimmunoassay , Adult , Aged , Aged, 80 and over , Cardiac Output, Low/blood , Chromatography, High Pressure Liquid , Drug Stability , Female , Humans , Male , Middle Aged , Natriuretic Peptide, Brain/blood , Quality Control , Reference ValuesABSTRACT
Adrenaline injection fluids aged between 3 and 33 years were analyzed with respect to oxidation and racemization. The oxidation was determined by ion-pair reversed phase HPLC, and the degree of racemization was determined by derivatization of the adrenaline isomers to diastereomeric forms and subsequently separated by reversed phase HPLC. 10% adrenaline was oxidized after about 11 years, while 10% L-adrenaline was converted to D-adrenaline after only 4 years. After about 4 years, the injections contained less than 90% active adrenaline.